Patients
PD‐L1, death, esophageal adenocarcinoma, tumor
TUMOR, GASTROESOPHAGEAL JUNCTION CANCER, ESOPHAGEAL ADENOCARCINOMA, MAY, ONCOLOGY, CPS, GASTRIC CANCER
From April 2017 to May 2019, 357 Chinese patients were assessed for eligibility in CheckMate 649. Among these, 208 patients were randomized to receive nivolumab plus chemotherapy (n = 99) or chemotherapy alone (n = 109); 99 patients in the nivolumab plus chemotherapy group and 106 patients in the chemotherapy group received at least one dose of the assigned treatment (Figure Trial profile for Chinese patients. OS, overall survival; PFS, progression‐free survival. Baseline demographics and clinical characteristics
Abbreviations: CPS, combined positive score; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFOX, oxaliplatin, leucovorin and 5‐fluorouracil; GC, gastric cancer; GEJC, gastroesophageal junction cancer; LLN, lower limit of normal; PD‐L1, programmed death ligand 1; XELOX, capecitabine and oxaliplatin.Based on case report form. All randomized patients had an ECOG PS of 0 or 1 based on interactive response technology.No Chinese patients with esophageal adenocarcinoma were enrolled.Includes indeterminate tumor cell PD‐L1 expression.Per World Health Organization histological classification.Patients who received at least one dose of the assigned treatment.